Light Mode
$16.06 ↑ +0.00 (+0.00%) Trading Up from the previous close of $16.06, $0.69 below the day’s high of $16.75
+13.49 (+524.90%) / 6M
Momentum, market sentiment, and recent alerts
REPL reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +53.7%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.